Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
JOENJA vs ACEPHEN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
JOENJA (lenvatinib) is a tyrosine kinase inhibitor that inhibits multiple receptor tyrosine kinases including VEGFR1-3, FGFR1-4, PDGFRα, RET, and KIT. It blocks tumor angiogenesis and proliferation.
ACEPHEN (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, particularly COX-2, reducing prostaglandin synthesis. It has weak peripheral COX inhibition and minimal anti-inflammatory effect.
Differentiated thyroid cancer (DTC) refractory to radioactive iodine,Renal cell carcinoma (RCC) in combination with everolimus,Hepatocellular carcinoma (HCC) first-line treatment in combination with pembrolizumab
Mild to moderate pain,Fever
JOENJA (lenalidomide) 2.5 mg orally once daily on days 1-21 of a 28-day cycle.
325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.
Terminal elimination half-life is approximately 12-15 hours in patients with normal renal function. This supports once-daily dosing in most indications. Half-life is prolonged in renal impairment, requiring dose adjustment.
Terminal elimination half-life: 1.0-1.5 hours in adults with normal renal function. Prolonged to 2-5 hours in hepatic impairment or elderly; requires dose adjustment in severe hepatic disease.
Primarily metabolized by CYP3A4 and aldehyde oxidase (AO). Minor pathways include CYP3A5 and CYP2C8.
Acetaminophen is primarily metabolized in the liver via glucuronidation (UGT1A1, UGT1A6, UGT1A9) and sulfation (SULT1A1, SULT1A3). A minor fraction is oxidized by cytochrome P450 enzymes (CYP2E1, CYP1A2, CYP3A4) to a reactive toxic metabolite (NAPQI), which is normally detoxified by conjugation with glutathione.
Primarily renal excretion of unchanged drug (approximately 70-80% of the dose). A small fraction (5-10%) is eliminated via feces via biliary excretion. The remainder is metabolized and excreted as inactive metabolites.
Renal: 90-95% as unchanged drug; tubular secretion and glomerular filtration. Biliary/fecal: <5%.
Approximately 90-95% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein. Binding is saturable at high concentrations and may be altered in disease states (e.g., hepatic impairment, hypoalbuminemia).
Approximately 10-20% bound to serum albumin; extensive tissue binding.
Volume of distribution is approximately 0.6-0.8 L/kg, indicating distribution into total body water. This suggests extensive extravascular distribution, with higher concentrations in well-perfused organs (liver, kidneys) and lower in adipose tissue.
Apparent Vd: 0.5-0.7 L/kg (30-40 L in a 70 kg adult). Distributions into CSF and breast milk.
Oral bioavailability is approximately 60-70%, with moderate interindividual variability. Food does not significantly affect absorption. No other relevant routes (e.g., topical) are available; bioavailability via IV is 100%.
Oral: 85-90% (first-pass metabolism minimal). Rectal: approximately 70-80% of oral bioavailability.
For Cr Cl 30-60 m L/min: 2.5 mg orally once daily; for Cr Cl <30 m L/min (not on dialysis): 1.25 mg orally once daily; for ESRD on dialysis: 2.5 mg orally once daily, dose after dialysis.
GFR 10-50 m L/min: 650 mg every 6 hours; GFR <10 m L/min: 650 mg every 8 hours.
No dose adjustment required for mild to moderate hepatic impairment; not studied in severe impairment (Child-Pugh C).
Child-Pugh Class A: no adjustment; Child-Pugh Class B: maximum 2 g/day; Child-Pugh Class C: maximum 1 g/day.
Safety and efficacy not established in pediatric patients under 18 years.
10-15 mg/kg/dose orally every 4-6 hours; maximum 75 mg/kg/day or 4 g/day, whichever is less.
No specific dose adjustment; monitor renal function and adjust dose based on Cr Cl.
Start at lowest effective dose (325 mg every 6 hours); avoid exceeding 3 g/day unless closely monitored.
None.
Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4,000 milligrams per day, and often involve more than one acetaminophen-containing product.
Hypertension (including hypertensive crisis),Cardiac dysfunction (reduced LVEF),Arterial thromboembolic events,Hepatic impairment (including hepatotoxicity),Renal impairment (including proteinuria),Hemorrhage,Gastrointestinal perforation or fistula,QT prolongation,Reversible posterior leukoencephalopathy syndrome (RPLS),Thyroid dysfunction,Wound healing complications
Risk of severe liver injury with doses >4000 mg/day; use caution with hepatic impairment, chronic alcoholism, malnutrition, or concomitant hepatotoxic drugs; avoid exceeding recommended dose; limit use to 10 days for pain or 3 days for fever unless directed by physician; serious skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis) have occurred.
None known
Hypersensitivity to acetaminophen or any component of the formulation; severe hepatic impairment or active liver disease.
Avoid grapefruit, grapefruit juice, and star fruit as they inhibit CYP3A4 and may increase lapatinib levels. Administer on an empty stomach; food, especially high-fat meals, can increase lapatinib AUC by 2-3 times and Cmax by 3-4 times, increasing toxicity risk.
Alcohol: increased risk of hepatotoxicity. Avoid concurrent use. Food: no significant interaction, but taking with food may reduce minor gastrointestinal irritation.
First trimester: Based on animal studies, there is evidence of teratogenicity including cardiovascular and neural tube defects. Human data are limited; however, the drug should be avoided in the first trimester unless benefits outweigh risks. Second/third trimester: May cause fetal growth restriction and oligohydramnios; use only if clearly needed.
Pregnancy Category C. First trimester: potential risk of neural tube defects and orofacial clefts (limited human data, animal studies show embryotoxicity). Second and third trimesters: NSAID exposure associated with oligohydramnios, premature ductus arteriosus constriction, and fetal renal impairment. Avoid in third trimester.
Unknown if excreted in human milk. The M/P ratio has not been determined. Due to potential for serious adverse reactions in nursing infants, breastfeeding is not recommended during treatment and for at least 1 month after last dose.
Excreted into breast milk in low concentrations (M/P ratio approximately 0.10). Considered compatible with breastfeeding; however, use lowest effective dose for shortest duration given potential for neonatal adverse effects (e.g., thrombocytopenia, renal dysfunction).
Due to increased plasma volume and renal clearance during pregnancy, higher doses may be required. Consider dose titration based on therapeutic drug monitoring and clinical response. No specific dose adjustment is established; individualize therapy.
No standard dose adjustments recommended; however, due to increased plasma volume and metabolism in pregnancy, higher doses may be required to achieve therapeutic effect. Avoid near term.
JOENJA (lapatinib) is a dual tyrosine kinase inhibitor of EGFR and HER2. Use with caution in patients with severe hepatic impairment (Child-Pugh C); reduce dose to 750 mg/day. Monitor for QT prolongation, especially in patients with hypokalemia or hypomagnesemia, or those on concurrent QT-prolonging drugs. Diarrhea is common (grades 1-2 in ~50%); premedicate with loperamide and ensure adequate hydration. Hepatotoxicity (ALT >5x ULN) occurs in ~2%; discontinue if severe. Avoid concurrent strong CYP3A4 inducers (e.g., rifampin) as they decrease lapatinib AUC by up to 70%.
ACEPHEN (acetaminophen) is commonly used for mild to moderate pain and fever. Avoid exceeding 4 g/day in adults to prevent hepatotoxicity. In patients with hepatic impairment, reduce maximum daily dose to 2 g. Consider acetylcysteine for overdose. Onset of action is 15-30 minutes orally.
Take JOENJA on an empty stomach, at least 1 hour before or 1 hour after a meal; do not take with food as it increases absorption unpredictably.,Do not crush, chew, or split tablets; swallow whole.,If you miss a dose, take it as soon as you remember unless it is less than 12 hours before the next dose; then skip the missed dose.,Avoid grapefruit, grapefruit juice, and star fruit during treatment.,Use effective non-hormonal contraception during treatment and for at least 1 week after the last dose.,Report severe or persistent diarrhea, yellowing of skin or eyes, dark urine, or unusual bruising/bleeding to your healthcare provider.
Do not exceed 4000 mg (4 grams) in 24 hours.,Avoid drinking alcohol while taking this medication.,Do not combine with other products containing acetaminophen.,Take with food if stomach upset occurs.,Seek immediate medical help if you experience symptoms of liver damage: yellowing of skin/eyes, dark urine, severe abdominal pain.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about JOENJA vs ACEPHEN, answered by our medical review team.
JOENJA is a Sphingosine 1-Phosphate Receptor Modulator that works by JOENJA (lenvatinib) is a tyrosine kinase inhibitor that inhibits multiple receptor tyrosine kinases including VEGFR1-3, FGFR1-4, PDGFRα, RET, and KIT. It blocks tumor angiogenesis and proliferation.. ACEPHEN is a Non-Opioid Analgesic that works by ACEPHEN (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, particularly COX-2, reducing prostaglandin synthesis. It has weak peripheral COX inhibition and minimal anti-inflammatory effect.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between JOENJA and ACEPHEN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of JOENJA is: JOENJA (lenalidomide) 2.5 mg orally once daily on days 1-21 of a 28-day cycle.. The standard adult dose of ACEPHEN is: 325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between JOENJA and ACEPHEN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. JOENJA is classified as Category C. First trimester: Based on animal studies, there is evidence of teratogenicity including cardiovascular and neural tube defects. Human data are limited; however, the drug should be . ACEPHEN is classified as Category C. Pregnancy Category C. First trimester: potential risk of neural tube defects and orofacial clefts (limited human data, animal studies show embryotoxicity). Second and third trimest. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.